# SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

> **NCT07284992** · PHASE2 · RECRUITING · sponsor: **Shandong Provincial Hospital** · enrollment: 208 (estimated)

## Conditions studied

- Rectal Cancer
- Advanced Stage Colorectal Cancer
- Radiotherapy

## Interventions

- **COMBINATION_PRODUCT:** short-term radiotherapy combined with Adebrelimab and capox
- **COMBINATION_PRODUCT:** long-term radiotherapy combined with Adebrelimab and capox

## Key facts

- **NCT ID:** NCT07284992
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2028-11-30
- **Final completion:** 2033-06-30
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284992, "SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07284992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*